New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:49 EDTBCRXBioCryst, HHS extend peramivir agreement for 31 days
BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 7, 2014
12:42 EDTBCRXBioCryst announces RAPIVAB trial results for the treatment of influenza
Subscribe for More Information
September 5, 2014
10:57 EDTBCRXBioCryst falls after WHO posts document on potential Ebola therapies
Shares of BioCryst Pharmaceuticals (BCRX) are sliding in early trading after the World Health Organization posted documents ahead of a meeting it is holding to discuss the recent Ebola outbreak and potential strategies to combat the disease. WHAT'S NEW: This week, on September 4-5, WHO is bringing together technical experts from the groups developing Ebola interventions along with people working to overcome Ebola virus disease, the group stated on its website. WHAT'S NOTABLE: In a background document on potential Ebola therapies and vaccines, WHO wrote regarding the availability and feasibility of BCX4430 from Biocryst that the drug "needs animal treatment and protection data for EVD before it can be considered. No material is currently available for field use." PRICE ACTION: Shares of BioCryst are down 50c, or 3.76%, to $12.28. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use